DONGBAO TO ACQUIRE FERRING'S MALMÖ MANUFACTURING OPERATION
Symposium looks at potential of mesalazine to prevent colorectal cancer in IBD
(14th United European Gastroenterology Week, 21-25 October 2006)
Ferring Pharmaceuticals Officially Opens Its Production Site and Global Administrative Headquarters
Assisted Reproductive Technology helps address demographic challenge in Europe
Degarelix, a novel GnRH blocker from Ferring, moves into phase III
Ferring and Astellas enter a license agreement on Degarelix for the treatment of prostate cancer in Japan
Ferring International Center S.A.Ch. de la Vergognausaz 50CH-1162 Saint-PrexSwitzerlandTel: +41 58 301 00 00Fax: +41 58 301 00 10
Email for media enquiries only.For other queries, please see our Contact page.
FERRING INTERNATIONAL CENTER S.A.CH. DE LA VERGOGNAUSAZ 50 1162 SAINT-PREXSWITZERLAND
TEL: +41 58 301 00 00FAX: +41 58 301 00 10
This global corporate website provides general information about the global Ferring Group. For information about Ferring or its products in a specific country, please select your country in the Global Locator. FERRING, the FERRING PHARMACEUTICALS logo and other Ferring product trade names are trademarks of Ferring B.V. save where indicated otherwise. ©2017 Ferring B.V.